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Abstract
Objectives
Adjuvant paclitaxel and trastuzumab has been shown to be an effective regimen with low
risk of cancer recurrence and treatment-related toxicities in early-stage node-negative,
HER2-positive breast cancer. We investigated the cost-effectiveness of this regimen.
Methods
A Markov-based microsimulation model with six health states is used to simulate four adju-
vant therapy options for women with early-stage node-negative, HER2-positive breast can-
cer at different age groups. The four treatment arms are 1) adjuvant paclitaxel and
trastuzumab (TH), 2) doxorubicin, cyclophosphamide, paclitaxel and trastuzumab (ACTH),
3) docetaxel, carboplatin and trastuzumab (TCH), and 4) no adjuvant trastuzumab (NT).
Data from randomized trials were used to estimate treatment efficacy. Societal perspective
was used in this cost-effectiveness analysis. Costs were measured in 2016 US dollars (US
$) and quality-adjusted life-years (QALYs) was used for health outcomes. Sensitivity analy-
ses were performed to evaluate the impact of uncertainty in parameter estimation.
Results
We found that 40-year-old women undergoing TH treatment would have an average of 16.17
QALYs for the cost of $178,650 when lifetime horizon is used. Compared to NT, TH has incre-
mental cost-effectiveness ratios ranged from $10,584 (ages 40–49) to $84,981 (age 80+) per
additional QALYs. The sensitivity analysis showed that TH is cheaper and leads to higher
QALYs compared to both ACTH and TCH for all age groups and time horizons.
Conclusions
TH is cost-effective for all age groups in the base case scenario and in the sensitivity analy-
sis. In order to reduce the parameter uncertainty, clinical trials with longer follow-up times
are needed.
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1 Introduction
Breast cancer remains the most common cancer among the US women with an estimated
252,710 diagnoses and over 40,000 deaths in 2017 [1]. Human epidermal growth factor recep-
tor type 2 (HER2) is amplified and overexpressed in 15–20% of breast cancers and historically
has been associated with inferior disease-related outcomes [2,3]. Trastuzumab, a humanized
monoclonal antibody to the HER2 protein, in combination with chemotherapy has been
shown to improve disease outcomes and survival in the adjuvant setting with early-stage
HER2-positive breast cancer [4–6]. These pivotal clinical trials established doxorubicin, cyclo-
phosphamide, paclitaxel and trastuzumab (ACTH) and non-anthracycline based regimens
such as docetaxel, carboplatin and trastuzumab (TCH) as standard of care adjuvant treatment
for HER2-positive breast cancer.
Because the majority of patients enrolled in the early trastuzumab studies had higher-risk
disease with larger, node-positive tumors, and with concerns of toxicities from adjuvant che-
motherapy, there has been increasing interest in de-escalation of therapy for low-risk disease.
Tolaney and colleagues recently reported disease-related outcomes and low toxicities with a
novel paclitaxel and trastuzumab (TH) adjuvant therapy regimen in early-stage node-negative
tumors with risk of disease recurrence of less than 2% at 3 years [7]. Despite the short duration
of follow-up, based on promising reported outcomes and tolerability, TH is being increasingly
utilized in clinical practice for adjuvant treatment of low-risk HER2-positive disease.
With the clinical benefit of adjuvant trastuzumab alongside the escalating costs of cancer
treatments, we sought to assess the cost-effectiveness of the TH regimen as compared to stan-
dard of care, ACTH and TCH regimens for small, node-negative HER2-positive breast cancer
in the United States using a Markov modeling approach. We also included an arm of no adju-
vant trastuzumab (NT), based on retrospective reports of outcomes reported in this context
[8,9].
2 Methods
2.1 Study design
A Markov state-transition microsimulation model was developed in MATLAB 2016 software
to evaluate the cost-effectiveness of four adjuvant treatment strategies for early-stage node-
negative, HER2-positive breast cancer (Fig 1; see also S1 and S2 Figs). The Markov model uses
a cycle length of one month to simulate 10,000 patients in each arm representing different
treatment strategies. As per the study by Kurian et al.[10], the model evaluated the lifetime
health outcomes beyond the 4 & 5 years median follow-up data available from the randomized
clinical trials [6,7] to estimate the long-term impact on health outcomes, treatments’ costs and
quality of life. This study follows the Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) [11], the CHEERS checklist associated with this study is included in the
Supplemental Materials (S1 Checklist).
We presented the results in terms of incremental cost-effectiveness ratios (ICERs) using
two different effectiveness measures: cost per quality-adjusted life-years (QALYs) gained and
cost per life-years (LYs) gained. Following the recommendations of the Panel on Cost-Effec-
tiveness in Health and Medicine, we performed our analysis using the societal perspective and
discounted both future costs and future QALYs at 3% in the base case analysis [12]. We pre-
ferred the societal perspective since it reflects the viewpoint of the various decision makers
considering the broad allocation of resources across the population and allows the comparison
of the present study to other programs used for other diseases and health conditions. [12] Fur-
thermore, because our study could be used by various decision makers such as the insurance
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companies, individual payers, and providers, limiting the perspective to only one type of deci-
sion makers would our results less useful for others.
Our model considers five age groups (40–49, 50–59, 60–69, 70–79 and 80+ year-old
women) with early-stage node-negative HER2-positive breast cancer. Age groups 40–49 and
50–59 represent the median age group of the participants in the addressed randomized trials
[6,7]. We used age-based mortality rates to evaluate the cost-effectiveness for age groups, 60–
69, 70–79 and 80+ year-old women. Assuming the relapse rate will decline beyond the median
follow-up period [10], we extrapolate the relapse rates reported in [6,7] for the subsequent
years with a similar rate.
2.2 Treatment strategies
This cost-effectiveness analysis evaluates and compares the clinical and cost outcomes of four
alternative adjuvant therapies. The first arm represents the no adjuvant trastuzumab (NT) which
is based on the control arms of the NSABPB-31 and NCCTG9831 clinical trials [4]. The second
arm simulates the TH regimen [7], where paclitaxel is administered at 80 mg/square meter of
body-surface area weekly for three months with a trastuzumab dose of 4 mg/kg of body weight on
day 1 and then, 2 mg of intravenous trastuzumab per kilogram weekly, for a full year.
ACTH and TCH regimens were considered as comparative programs [6]. These two regi-
mens are commonly used in practice and the clinical trials on these therapies included early-
stage node-negative breast cancer patients. In the third arm, patients receive ACTH where
cyclophosphamide and doxorubicin are administrated at 600 mg/m2 and 60 mg/m2 respec-
tively for 4 cycles every 3 weeks. Then, patients receive docetaxel 100 mg/m2 for 4 doses every
3 weeks and 52 weeks of trastuzumab [6]. In the fourth arm, patients receive TCH where car-
boplatin is administered at 6 mg per milliliter per minute and docetaxel at 75 mg/m2 for 6
cycles and every 3 weeks along with trastuzumab concurrently. Then, patients receive trastuzu-
mab alone to complete a year of treatment [6].
Fig 1. State-transition Markov model represents breast cancer treatment and follow-up states. This figure represents the conceptual model used in this
study.
https://doi.org/10.1371/journal.pone.0217778.g001
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2.3 Model structure
The Markov model is essentially divided into two sub-models: adjuvant chemotherapy sub-
model and follow-up sub-model (Fig 1). Markov sub-model for the adjuvant chemotherapy
consists of the following 5 states: adjuvant therapy (state 1), low toxicity (state 2), hospitaliza-
tion due to high toxicity (state 3), alive with relapse-free (state 4), and death due to any cause
(state 6). All patients start the simulation at the adjuvant therapy state (state 1) and transitions
among various states occur according to a Markov process. There are three levels of toxicity
due to adjuvant chemotherapy based on the grading system: well, low toxicity, and high toxic-
ity. No adverse effects (grade 0) are represented by “Well” when patients continue to undergo
treatment, minimal or moderate adverse events (grade 1 and 2) are represented by ‘‘low toxic-
ity,” and severe or catastrophic adverse events (grade 3 and 4) are represented by ‘‘high toxic-
ity”[13]. If a patient receives adjuvant therapy with trastuzumab, the adjuvant therapy sub-
model runs for 12 months; and if she receives no adjuvant trastuzumab (NT), the sub-model
runs for 6 months where transitions occur on a monthly basis.
Once a patient completes adjuvant therapy or quits adjuvant therapy prematurely, she
moves directly to the follow-up sub-model and starts in the “alive with relapse-free” state (state
4). This sub-model consists of three states. Two of these states are identical to those in the adju-
vant chemotherapy sub-model (states 4 and 6). The third state is “alive with relapse” (state 5).
Upon a breast cancer recurrence or a new primary breast cancer event, the patient undergoes
the same treatment she had in the adjuvant chemotherapy sub-model one more time and
remains at the “alive with relapse” state until death. This assumption is made only for local
recurrence or a new primary breast cancer which would be treated with curative intent with
adjuvant therapy. Due to limited data, we assumed similar relapse probability for all age groups
in each of the adjuvant therapy arms. Patients are followed until they die (i.e., the time horizon
of the study is the lifetime of the patient).
2.4 Transition probabilities
We adjusted all rates to estimate the monthly health-state transition probabilities (Table 1).
We used age-based mortality rates to estimate the monthly death probability from the National
Center for Vital Statistics [14] since no patients following TH regimen died due to breast can-
cer. For the NT arm, we estimated breast cancer recurrence rates based on the study by Kurian
et al.[10], which are based on the control arms of the NSABPB-31 and NCCTG9831 clinical
trials [4]. In all trastuzumab arms, we estimated the efficacy and safety input parameters for
each regimen using the most recent randomized clinical trials [6,7]. Beyond the median fol-
low-up period of these trials, we considered that the relapse rate would decline as assumed by
Kurian et al. [10]. We considered distant, regional, and local recurrence as well as new contra-
lateral primary breast cancer in estimating the monthly rate of relapse. For the ACTH and
TCH therapies, we estimated the relapse rate based only on the group of patients with early-
stage node-negative breast tumors to ensure a fair comparison. Additionally, we assumed that
if a patient had to quit the therapy for any reason, her monthly relapse rate would increase lin-
early to 0.0126 [8]. We also assumed no breast cancer relapse during the treatment period.
2.5 Treatment-related toxicity
In this study, we considered toxicity events resulted from using trastuzumab in the adjuvant
therapy. Low and high toxicity rates were derived from the respective randomized trials [6,7].
We assumed that patients quit the treatment after one month if they did not recover from a
toxicity event as in the trial protocol of Tolaney et al. [7]. We assumed that 70% of the patients
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Table 1. Base case transition probabilities.
Arm Parameter Name Age Base Case Monthly Probability (Mean) Range / SD Reference
Control arm (NT) Death from all states, years 1–2
(except alive with relapse state)
40–49 0.00040 Not varied [10]
50–59 e 0.00102 Not varied [10]
60–69 e 0.00236 Not varied [10]
70–79 e 0.00548 Not varied [10]
80 and over e 0.01485 Not varied [10]
Death from all states, years >2
(except alive with relapse state)
(age-specific mortality)
40–49 0.00034 Not varied [10,14]
50–59 0.00078 Not varied [10,14]
60–69 0.00161 Not varied [10,14]
70–79 0.00403 Not varied [10,14]
80 and over 0.01485 Not varied [10,14]
Relapse, years 1–2 a,d All age groups 0.007 20% +/- [10]
Relapse, years 3–4 a,d 0.0085 20% +/- [10]
Relapse, years 5–8 a,d 0.0045 20% +/- [10]
Relapse, years 9–10 a,d 0.0032 20% +/- [10]
Relapse, years�11 a,d 0.0016 20% +/- [10]
Death from relapse 0.02734 50% +/- [10]
TH Death from all states
(except alive with relapse state)
(age-specific mortality)
40–49 0.00034 Not varied [7,14]
50–59 0.00078 Not varied [7,14]
60–69 0.00161 Not varied [7,14]
70–79 0.00403 Not varied [7,14]
80 and over 0.01485 Not varied [7,14]
Relapse, years 1–2 a,d All age groups 0.00042 20% +/- [7,10]
Relapse, years 3–4 a,d 0.00051 20% +/- [7,10]
Relapse, years 5–8 a,d 0.00027 20% +/- [7,10]
Relapse, years 9–10 a,d 0.00019 20% +/- [7,10]
Relapse, years�11 a,d 0.00010 20% +/- [7,10]
Death from relapse 0.02734 50% +/- [10]
High toxicity event 0.00170 [.00021 - .003] [7]
Quit treatment due to high toxicity b 0.00340 10% +/- [7]
Low toxicity event c 0.00761 [.0047 -.0165] [7]
Quit treatment due to low toxicity b 0.00148 10% +/- [7]
ACTH Death from all states
(except alive with relapse state)
(age-specific mortality)
40–49 0.00034 Not varied [14]
50–59 0.00078 Not varied [14]
60–69 0.00161 Not varied [14]
70–79 0.00403 Not varied [14]
80 and over 0.01485 Not varied [14]
Relapse, years 1–2 a,d All age groups 0.00094 20% +/- [6,10]
Relapse, years 3–4 a,d 0.00114 20% +/- [6,10]
Relapse, years 5–8 a,d 0.00060 20% +/- [6,10]
Relapse, years 9–10 a,d 0.00043 20% +/- [6,10]
Relapse, years�11 a,d 0.00021 20% +/- [6,10]
Death from relapse 0.02734 50% +/- [10]
High toxicity event 0.00980 [.000078 - .058] [6]
Quit treatment due to high toxicity b 0.00340 10% +/- [7]
Low toxicity event c 0.04250 [.0017 - .247] [6]
Quit treatment due to low toxicity b 0.00148 10% +/- [7]
(Continued)
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who quit the treatment quit due to high toxicity and 30% of them quit due to low toxicity as
reported by [4].
2.6 Utilities
We used latest published studies to estimate the quality-of-life for the adjuvant therapies, low
and high toxicities, and breast cancer relapse (Table 2). For low toxicity events, we estimated
the utility based on the utility of chemotherapy-induced nausea and vomiting (0.85) for
patients who are undergoing adjuvant therapy with trastuzumab. For hospitalization due to
high toxicity, we used the mean utilities of patients with febrile neutropenia (0.47), congestive
heart failure (0.87), cardiac toxicity with symptoms (0.64) and acute myeloid leukaemia and/or
myelodysplastic syndrome (0.26). On the other hand, we applied a utility of (0.78) for the
ACTH adjuvant therapy and a utility of (0.81) for the NT therapy. Due to limited data, we
assumed that TCH adjuvant therapy has similar utility as ACTH and we assumed a mid-point
utility of (0.795) for the TH regimen since it is expected to cause less toxicity compared to both
TCH and ACTH [6,7]. We did a sensitivity analysis on this parameter.
2.7 Resource use and costs
Using the medical care component of the consumer price index, we converted all costs into
2016 US dollars (Table 2). For each therapy, we considered the costs of monthly oncologist
visit, drug infusion, toxicity monitoring, as well as costs due to being out of work and travel-
related costs. We estimated these costs from publications which incorporated data from the
Centers for Medicare & Medicaid Services and the US Bureau of Labor Statistics [10,15]. We
Table 1. (Continued)
Arm Parameter Name Age Base Case Monthly Probability (Mean) Range / SD Reference
TCH Death from all states
(except alive with relapse state)
(age-specific mortality)
40–49 0.00034 Not varied [14]
50–59 0.00078 Not varied [14]
60–69 0.00161 Not varied [14]
70–79 0.00403 Not varied [14]
80 and over 0.01485 Not varied [14]
Relapse, years 1–2 a,d All age groups 0.00131 20% +/- [6,10]
Relapse, years 3–4 a,d 0.00159 20% +/- [6,10]
Relapse, years 5–8 a,d 0.00084 20% +/- [6,10]
Relapse, years 9–10 a,d 0.00060 20% +/- [6,10]
Relapse, years�11 a,d 0.00030 20% +/- [6,10]
Death from relapse 0.02734 50% +/- [10]
High toxicity event 0.00920 [.000079 - .053] [6]
Quit treatment due to high toxicity b 0.00340 10% +/- [7]
Low toxicity event c 0.03983 [.0018 - .230] [6]
Quit treatment due to low toxicity b 0.00148 10% +/- [7]
a Considering the ratio of the NT arm.
b We assumed the same probability as in the TH arm given the absence of data—applied for all trastuzumab arms.
c We used the ratio between high and low toxicity in the TH to estimate the low toxicity ratio here.
d Probability of relapse increases linearly if a patient quits the treatment for any reason / toxicity.
e We used age-specific mortality ratio to come up with probability for the different age groups.
Abbreviations: ACTH, doxorubicin, cyclophosphamide, paclitaxel and trastuzumab regimen; NT, no adjuvant trastuzumab regimen; TCH, docetaxel, carboplatin and
trastuzumab regimen; TH, adjuvant paclitaxel and trastuzumab regimen.
https://doi.org/10.1371/journal.pone.0217778.t001
Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage breast cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0217778 June 5, 2019 6 / 14
estimated the total costs of the adjuvant chemotherapies using the Red Book average wholesale
drug prices as per clinical trials’ protocol. [6,7,15,17]. Based on the latest Common Terminol-
ogy Criteria for Adverse Events (CTCAE) v5.0, we estimated the cost of a hospitalization due
to high toxicity events based on grade 3–4 adverse events [13]. Thus, the estimated cost of hos-
pitalization due to high toxicity events accounts for the costs related to cardiotoxicity events
[15]. Furthermore, we used grade 1–2 adverse events to estimate the cost of low toxicity events
as they are minimal, asymptomatic, and do not impair daily living activities [10,13].
2.8 Validation and sensitivity analysis
We utilized several methods for validation. First, we ensured the face-validity of the model by
consulting our clinician co-author to share his clinical expertise on the model’s structure,
assumptions, and the input parameters. Additionally, all health-related parameters were
derived directly from the relevant clinical trials. Finally, a cross-validation was performed by
comparing our model’s results for the no adjuvant trastuzumab (NT) treatment strategy with
those of the study by Kurian et al. [10].
Table 2. Base case utilities and costs for various health states, treatments, breast cancer relapse, and toxicity levels.
Treatment Arm Parameter Name Age Base Case (Mean) Range / SD Reference
Health state utilities Monthly utility
NT Therapy All age groups 0.810 [.75 - .95] [10,15]
All trastuzumab arms Utility due to high toxicity All age groups 0.560 [.26 - .87] [10,16]
Utility due to low toxicity 0.850 .04 Beta
TH Adjuvant therapy All age groups 0.795 [.75 - .95] Assumed based on [6,10]
ACTH and TCH a Adjuvant therapy All age groups 0.780 [.6 -.95] [10,15]
All arms Patient utility before starting the treatment 40–49 0.84 0.002 Beta [16]
50–59 0.83 0.003 Beta
60–69 0.83 0.003 Beta
70–79 0.81 0.004 Beta
80 and over 0.78 0.006 Beta
Utility of relapse All age groups 0.55 20% +/- [10]
Utility after therapy (relapse-free) 0.90 [.85 - .95] [15]
Cost Monthly cost
2016 US dollars
NT Treatment cost b,c All age groups $5,896.59 20% +/- [10,15,17]
TH Treatment cost b,c All age groups $7,812.34 20% +/- [10,15,17]
TCH Treatment cost b,c All age groups $9,404.05 20% +/- [10,15,17]
ACTH Treatment cost b,c All age groups $11,452.91 20% +/- [10,15,17]
All trastuzumab arms High toxicity All age groups $2,730.0 [2068–5517] [15]
Low toxicity $212.00 20% +/- [10]
All arms Relapse-free state 40–49 $286.00 Not varied [10]
50–59 $311.50 Not varied
60–69 $382.50 Not varied
70 and over $425.50 Not varied
Death All age groups $10,000.00 [5000–20,000] [15]
a Assumed to be similar to the ACTH.
b The recurrence cost is similar.
c Includes drug, infusion, 15-minute oncologist visit monthly, cardiac monitoring, and costs of time lost from work and travel cost.
Abbreviations: ACTH, doxorubicin, cyclophosphamide, paclitaxel and trastuzumab regimen; NT, no adjuvant trastuzumab regimen; TCH, docetaxel, carboplatin and
trastuzumab regimen; TH, adjuvant paclitaxel and trastuzumab regimen.
https://doi.org/10.1371/journal.pone.0217778.t002
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We utilized different methods to perform sensitivity analyses in order to test the robustness
of the base case results. We conducted one-way and probabilistic sensitivity analyses to
account for uncertainty in model parameters. We varied the model parameters based on the
distributions as reported in Tables 1 and 2. For parameters with uncertainty reported in the
form of a range, we assumed triangular distribution by using the mean value as the mode. We
used common random numbers to compare different treatment alternatives [18]. We used
$50,000/QALYs as the willingness-to-pay (WTP) threshold [19].
Furthermore, we evaluated the cost-effectiveness for different age groups in 40 to 80 years
old. We determined the age-based ICER assuming all parameters are kept constant except for
the mortality rates, patient utility without the treatment, and the monthly cost of being at the
“alive with relapse-free” state. We also evaluated the cost-effectiveness of considered treat-
ments when different time horizons are used.
3 Results
3.1 Base case
The results of the base case analysis over a lifetime horizon for age group 40–49 years (Table 3)
show that the no adjuvant trastuzumab (NT) arm yields 9.57 QALYs and 18.87 LYs at a cost of
$108,821, the paclitaxel and trastuzumab regimen yields 16.17 QALYs (and 33.77 LYs) at a
cost of $178,650, the ACTH regimen yields 15.46 QALYs (and 32.25 LYs) at a cost of $221,974,
and the TCH regimen yields 15.02 QALYs (and 31.23 LYs) at a cost of $198,473. Compared to
the NT arm, the use of the TH regimen would incur an additional cost of $69,829 for an
expected gain of 6.6 QALYs (and 14.9 LYs). Hence, the incremental cost per QALY gained is
$10,584. Furthermore, the TH regimen is cheaper and leads to higher QALYs compared to
both ACTH and TCH regimens.
3.2 Impact of age and time horizon
Time horizon has a significant impact on the ICER (Fig 2; see also S3 Fig). The longer the time
horizon (i.e., the time that the effect of treatment on reducing relapse continues), the more
cost-effective is the TH regimen compared to the NT arm. If the time horizon for TH regimen
Table 3. Base case results for the 40–49 age group when lifetime horizon is used.
Adjuvant Treatment Total Cost
(2016 USD)
QALYs Incremental costs a Incremental QALYs a ICER
(Base case)
NT $ 108,821 9.57 $ -69,829 -6.6 —
TH $ 178,650 16.17 — — $ 10,584 / QALY b
ACTH $ 221,974 15.46 $ 43,324 -0.71 N/A a
TCH $ 198,473 15.02 $ 19,823 -1.15 N/A a
(Without adjustment for quality of life) Total Cost LYs Incremental costs Incremental LYs ICER
NT $ 108,821 18.87 $ -69,829 -14.9 —
TH $ 178,650 33.77 — — $ 4,688 / LY b
ACTH $ 221,974 32.25 $ 43,324 -1.52 N/A a
TCH $ 198,473 31.23 $ 19,823 -2.54 N/A a
a Not applicable.
b Relative to NT.
Abbreviations: ACTH, doxorubicin, cyclophosphamide, paclitaxel and trastuzumab regimen; ICER, incremental cost-effectiveness ratio; NT, no adjuvant trastuzumab
regimen; QALY, quality-adjusted life year; TCH, docetaxel, carboplatin and trastuzumab regimen; TH, adjuvant paclitaxel and trastuzumab regimen.
https://doi.org/10.1371/journal.pone.0217778.t003
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median follow-up period is four years (i.e., TH regimen has no additional benefit in reducing
relapse beyond four years), the regimen becomes not cost-effective. In our base case analysis,
we assumed that while the treatments reduce relapse through lifetime, the rate of reduction in
relapse probability is smaller after year 4. Across all age groups, the ICER for TH vs NT under
lifetime horizon is relatively close to that under a 12-year time horizon. Thus, extending the
time horizon beyond 12 years has a relatively small impact on the cost-effectiveness of TH.
The time horizon represents the maximum time that the TH is effective in reducing the
probability of relapse, the regimen leads to no reduction in relapse beyond the time horizon.
Abbreviations: ICER, incremental cost-effectiveness ratio; NT, no adjuvant trastuzumab;
QALY, quality-adjusted life year; TH, adjuvant paclitaxel and trastuzumab regimen.
In the base case analysis and with a WTP threshold of $50,000 per QALY, TH regimen is
cost-effective for time horizons of 12 years or longer and for patients aged between 40 and 79.
However, gains due to treatment become smaller and the TH regimen becomes less cost-effec-
tive as the patient is older. Nonetheless, TH regimen continues to be cheaper and leads to
higher QALYs compared to both ACTH and TCH regimens for all age groups (see S4 Fig).
3.3 Sensitivity analysis
We presented the results of one-way sensitivity analysis for the 40–49 age group with lifetime
horizon using a tornado diagram (Fig 3). The results are most sensitive to variations in the dis-
count rate, probability of relapse, and cost of adjuvant therapy. Both future costs and QALYs
were discounted from 0% to 5% [10,15]. The results are more robust to changes in all toxicity-
Fig 2. Impact of time horizon on the ICERs ($/QALY) for the TH vs. NT for different age groups.
https://doi.org/10.1371/journal.pone.0217778.g002
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related parameters, the probability of dying from relapse, and the utility of relapse as well as
cost of death.
Our sensitivity analysis on the impact of increasing only the cost of treatment based on the
TH regimen shows a very steady increase in the ICER of TH regimen compared to the NT
arm; whereas a relatively sharp increase in the ICER compared to both ACTH and TCH regi-
mens (see S5 Fig). At 20% and 50% increase in the cost of TH regimen, the TH regimen is no
longer cheaper than TCH and ACTH, respectively. Nevertheless, TH regimen is still cost-effec-
tive when compared to all treatment alternatives if the increase in the treatment costs is less
than 60%.
The probabilistic sensitivity analysis showed that the likelihood of the cost-effectiveness of
TH adjuvant therapy as compared with NT was 100% with a $50,000/QALY threshold (see S1
Table, S6 and S7 Figs).
4 Discussion
In this paper, we used a Markov microsimulation model to compare four strategies for treating
women with early-stage node-negative, HER2-positive breast cancers. Our base case analysis
shows an ICER of $10,584 per QALY for TH compared to NT when we assume that the impact
of TH on relapse rates is observed throughout the lifetime of a patient (with a smaller rate of
reduction in relapse rates beyond year 4). Our probabilistic sensitivity analysis confirms that
Fig 3. Tornado diagram of one-way sensitivity analyses for the 40–49 age group and lifetime horizon of the TH vs. NT arm. Abbreviations: ICER, incremental cost-
effectiveness ratio; NT, no adjuvant trastuzumab; TH, adjuvant paclitaxel and trastuzumab regimen.
https://doi.org/10.1371/journal.pone.0217778.g003
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the TH regimen is cost-effective in the base case for the 40–49 year–old age group, indicating
the robustness of our model and findings. TH regimen is cheaper and leads to higher QALYs
compared to both ACTH and TCH regimens for all age groups in the base case scenario as
well in the sensitivity analysis due to the relatively high probability of toxicity events and high
costs associated with ACTH and TCH.
Several studies reported the cost-effectiveness of widely accepted breast cancer therapies
and found favorable ICERs [10,15,20]. For instance, anthracycline-based adjuvant trastuzu-
mab regimen for a 49-year-old women with early-stage HER2-positive breast cancer had an
ICER of $39,892/QALY [10], adjuvant trastuzumab chemotherapy for women with HER2-po-
sitive breast cancer had an ICER of $26,417/QALY [15], and a more recent study by Hedden
et al. reported that the adjuvant trastuzumab chemotherapy for women with HER2-positive
breast cancer has an ICER of $13,095/QALY [20].
One-way sensitivity analysis shows that although discount rate, the probability of relapse,
and cost of TH are the most influential parameters affecting the ICERs, these parameters still
do not have any major impact on the ICERs. For instance, even if the cost of TH regimen is
increased by 60%, TH remains cost-effective.
Our study’s major limitation is related to the limited availability of follow-up data on the
efficacy of treatment regimens. Namely, our study uses the trial data from the study by Tolaney
et al. [7], in which patients were administered with paclitaxel and trastuzumab for 12 weeks,
followed by trastuzumab alone for nine months with a median follow-up time of four years.
Hence, our model uses this four years of follow-up data for the regimen’s efficacy and toxicity
and extrapolates these estimates to the further years. Since the effects of adjuvant trastuzumab
persist in reducing the risk of relapse even beyond the completion of adjuvant therapy, we
have assumed in our analysis continuing effect of adjuvant therapy with paclitaxel and trastu-
zumab beyond four years [21,22]. A very recent publication using the longer 7 year follow up
data [23] confirms that the trends observed in the study by Tolaney et al. still holds, alleviating
concerns about the short-term follow up period [7]. Conversely, if we limit the time horizon of
the analysis to four years as used in this trial, TH regimen rapidly loses its cost-effectiveness.
To overcome this limitation, we did a sensitivity analysis on the impact of time horizon used
in this study and found that the regimen is still cost-effective (with an ICER less than
$100,000/QALY) with a time horizon of six years or longer. Moreover, although the majority
of the patients in our data sources had a small tumor, some patients with large tumors were
included, therefore our definition of early-stage cancer is not limited to a particular size cut off
in our analysis. Similarly, our data sources make estimates using small sample sizes for node
negative tumors therefore estimates on recurrence may not be accurate. Furthermore, this
study uses trial data collected from an academic setting, therefore translation into the real-life
situation may not generate the same outcomes. Additionally, our current work utilizes cost
estimates from different studies conducted in different contexts. Our future work could
include conducting a micro-costing study of real financial data for more accurate estimation.
Nonetheless, our sensitivity analysis shows that the cost-effectiveness of TH for treating
women with early-stage node-negative, HER2-positive breast cancer is not highly sensitive to
costs.
The discovery of trastuzumab has revolutionized the treatment of HER2-positive breast
cancer with significant improvements in disease-free and overall survival. However, this does
come at a significant cost to the society. With excellent outcomes of low-risk HER2-positive
early breast cancer, de-escalation of therapy has generated interest both from an individual
patient perspective as well as the society as a whole. This has led to efforts to reduce adjuvant
therapies and the evolution of regimens like TH which we hereby show to be cost-effective
with an ICER of $10,584 per QALY compared to NT much below the $50,000 per QALY, a
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commonly used benchmark for cost-effectiveness [24–27]. Although, one year of trastuzumab
continues to be the standard of care adjuvant therapy, further efforts are needed to identify
potential biomarkers for potential de-escalation of therapy and reduction in cost and
toxicities.
In conclusion, based on the current data, the TH regimen has a low relapse risk and
improved overall survival in early-stage node-negative, HER2-positive breast cancer, alongside
being cost-effective compared to regimens like ACTH and TCH. While awaiting long-term
survival data, this regimen is increasingly being considered in clinical use.
5 Conclusions
Adjuvant paclitaxel and trastuzumab (TH) is cost-effective for women with early-stage node-
negative, HER2-positive breast cancer aged between 40 and 79 years old in the base case sce-
nario as long as the time horizon is longer than the 12 years. Similarly, TH remains cost-effec-
tive for women aged between 40 and 49 in the sensitivity analysis. Moreover, TH is cheaper
and leads to higher QALYs compared to both ACTH and TCH regimens for all age groups,
therefore clinicians should consider utilizing TH for treating women with early-stage node-
negative, HER2-positive breast cancer due to its effectiveness and low toxicity.
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